<DOC>
	<DOCNO>NCT02054442</DOCNO>
	<brief_summary>The investigator perform randomize phase II study investigate addition cetuximab MTX beneficial patient . Because data combination available investigator start phase Ib study investigate feasibility schedule .</brief_summary>
	<brief_title>A Study Combination Cetuximab Methotrexate Recurrent Metastatic Cancer Head Neck</brief_title>
	<detailed_description>The addition cetuximab cisplatin 5-FU recurrent metastatic squamous cell carcinoma head neck ( SCCHN ) show improvement overall survival ( OS ) , progression free survival ( PFS ) response rate ( RR ) . However , cisplatin 5-FU toxic cytostatics vulnerable recurrent metastatic SCCHN patient . As one primary goal patient palliation , patient treatment cisplatin , 5-FU cetuximab feasible owe low performance score ( PS 2 ) patient refusal receive chemotherapy , i.e . cisplatin 5-FU , possibly influence quality life negatively . Methotrexate cytostatic show modest activity recurrent metastatic SCCHN . The RR 14 20 % , median PFS 3 month , improvement OS , 6 month . Toxicity MTX low . Patients PS 2 treated MTX . Patients refuse treatment cisplatin , 5-FU cetuximab , frequently choose MTX palliative treatment . No data available combination cetuximab MTX . The investigator perform randomize phase II study investigate addition cetuximab MTX beneficial , i.e . improvement PFS , patient . Because data combination available investigator start phase Ib study investigate feasibility schedule .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Cytologically/histologicallyproven SCCHN Recurrent metastatic SCCHN At least one measurable lesion determine RECIST v1.1 require . Lesions previously irradiate area consider measurable unless clear evidence progression lesion since radiotherapy . No prior systemic treatment recurrent metastatic disease Primary site : ( 1 ) oral cavity , ( 2 ) oropharynx , ( 3 ) hypopharynx , ( 4 ) larynx , ( 5 ) unknown primary squamous cell carcinoma head neck region present originally lymph node metastasis ( N1N3 ) . Time prior treatment inclusion study ( &gt; 3 month ) . Palliative RT case painful bone metastasis allow phase II 4 week phase Ib Ineligible ( due medical comorbidities ) intolerant platinumbased therapy per medical history refuse cisplatinbased chemotherapy patient WHO performance status 02 . Age &gt; 18 year Adequate organ function laboratory parameter define : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109 /L Hemoglobin ( Hb ) ≥ 9 g/dl 5.6 mmol/l ( may achieve transfusion ) Platelets ( PLT ) ≥ 100 x 109/L AST ALT ≤ 2.5 x ULN ( upper limit normal ) Serum bilirubin ≤ 1.5 x ULN Calculated creatinine clearance MDRD &gt; 60ml/min Recovered adverse event ( AEs ) previous anticancer therapy . AEs related prior radiotherapy allow . Written inform consent Serious active infection Patients ( M/F ) reproductive potential implementing adequate contraceptive measure Prior treatment EGFR inhibitor MTX Concomitant ( within 4 week randomization ) administration experimental drug investigation Concurrent treatment anticancer therapy . Central nervous system involvement Lung fibrosis Pleural effusion ascites third space effusion History another malignancy within 2 year prior start study treatment , except cure basal cell carcinoma skin , excise carcinoma situ cervix , head neck cancer . Pregnancy lactation Any condition would , Investigator 's judgment , preclude patient 's participation clinical study due safety concern compliance clinical study procedure , e.g . infection/inflammation , intestinal obstruction , social/psychological complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>methotrexate</keyword>
	<keyword>squamous cell carcinoma head neck</keyword>
	<keyword>palliative chemotherapy</keyword>
</DOC>